IQVIA Holdings stock

IQV · NYSE · USD

Compare IQVIA Holdings
$257.60Change from previous close: −2.69%Absolute change: −$7.13

Close · November 17, 2026

Price history

+20.26% over the period

1 year: from $216.12 (November 17, 2025) to $259.91 (November 17, 2026), +20.26%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$259.91
October 30, 2026$267.33
September 30, 2026$268.85
August 31, 2026$261.19
July 31, 2026$235.02
June 30, 2026$193.22
May 29, 2026$182.21
April 30, 2026$158.37
March 31, 2026$170.54
February 27, 2026$178.81
January 30, 2026$230.15
December 31, 2025$225.41
November 28, 2025$230.01
November 17, 2025$216.12

At a glance

  • The company

    Provides clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries

  • Latest results

    Quarter to September 30, 2026 · EPS $3.34 (estimate $3.25)

TickerLandia's take on IQVIA Holdings

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$154.50
52-wk high$284.50

−9.46% from the 52-week high

Analysts · 20 analysts

Average target$311.89+21.07% vs. price

Buy 18 · Hold 2 · Sell 0 · Strong buy

TickerLandia Fingerprint: IQVIA Holdings

Compared with similar companies: very low financial strength and very strong momentum.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

IQVIA Holdings is cheaper than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), IQVIA Holdings's P/E today is 33.2, below the median of its last 10 fiscal years (46.4; between 17.1 and 161.8 from 2016 to 2025). IQVIA Holdings's P/E (trailing 12 months): 31.5, −9% against the median of a group of 9 similar companies (34.5).

P/E compared with its history

Compared with 9 similar companies

IQVIA Holdings's metrics compared with similar companies
MetricIQVIA HoldingsPosition in the groupBand
P/E (trailing 12 months)31.5Middle
Forward P/E18.2Low
Operating margin13.9%Middle
ROE21.4%Middle
Debt/equity2.40High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: IQVIA Holdings. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$4.43B

Latest quarter · Q3 2026

Net income

$350M

Latest quarter · Q3 2026

Quarterly net margin

7.9%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$42.63B
P/E
31.5
EPS
$8.22
Volume
983.59K
Daily trading
€366.92M
Dividend yield
0.00%

How IQVIA Holdings is changing

All results
  • Revenue grew 7.5% a year on average over the last 5 years

  • Profits turn into cash: free cash flow equal to 138% of net income

  • Shares outstanding down 11.0% in 5 years

Returns

IQVIA Holdings returns

$1,000 invested in IQVIA Holdings 5 years ago, on November 17, 2021, would be worth $983 today: −1.72% in total, −0.35% per year. This is the price return only: dividends are excluded.

PeriodIQVIA HoldingsS&P 500$1,000 becomes
1 month−2.25%−3.17%$978
6 months+52.32%+0.11%$1,523
Year to date+15.31%+8.34%$1,153
1 year+20.26%+11.15%$1,203
3 years+26.92%+64.30%$1,269
5 years−1.72%+58.18%$983
10 years+227.01%+239.10%$3,270

Over the last 6 months it has done better than 89% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

IQVIA Holdings: technical analysis

IQVIA Holdings shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 8.8% below its all-time closing high ($282.61, December 30, 2021).

Trend
No clear trend
RSI (14 sessions)
40
Between 30 and 70
vs 200-session average
+21.89%

Support and resistance

Price areas where IQVIA Holdings has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$274.49+6.56%3 touches, last on October 6, 2026
  2. Last price$257.60
  3. Support$252.21−2.09%4 touches, last on November 3, 2026
  4. Support$245.61−4.66%2 touches, last on January 27, 2026
  5. Support$234.03−9.15%2 touches, last on August 17, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.70
Volatility (60 sessions, annualised)
26.8%
Largest fall in the last year
−35.87%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

IQVIA Holdings: seasonality

Average monthly price change over 14 years

+0.4%Jan+0.1%Feb−2.2%Mar+0.9%Apr+2.0%May+3.6%Jun+9.7%Jul+1.1%Aug−3.0%Sep−0.1%Oct+3.7%Nov+1.3%Dec

Over the last 14 years, the strongest month for IQVIA Holdings has been July: +9.67% on average, positive in 12 years out of 14. The weakest has been September: −3.04% on average, positive in 4 years out of 14. November, the current month, has been positive in 9 years out of 13 (+3.68% on average).

Show chart data
MonthAverageMedianPositive years
January+0.45%+2.47%9 of 13
February+0.07%−1.40%6 of 13
March−2.18%+0.18%7 of 13
April+0.86%−3.44%4 of 13
May+2.04%+2.56%8 of 13
June+3.57%+2.22%10 of 14
July+9.67%+8.19%12 of 14
August+1.09%+2.16%8 of 14
September−3.04%−2.36%4 of 14
October−0.12%−2.81%5 of 14
November+3.68%+2.86%9 of 13
December+1.27%+0.99%7 of 13

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

IQVIA Holdings and its competitors

Based in Durham, North Carolina, and in existence since 1982, IQVIA Holdings Inc. serves drug developers, biotechnology firms, device makers and consumer health companies with data, analytics and research services. Its activities include cloud-based software for commercial teams, real-world evidence studies, consulting on advanced analytics, clinical trial management, central laboratory and genomic testing, and contract sales with medical affairs support. Customers are located in the Americas, Europe, Africa and the Asia-Pacific region. A biosimilar development collaboration with Kexing Biopharm is also part of its work.

Headquarters
Durham, United States
Employees
95,000
Founded
1982
Chief executive
Ari Bousbib
IQVIA Holdings and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
IQVIA HoldingsIQV$42.63B13.9%31.5+52.32%
NateraNTRA$41.83B-8.5%—+54.26%
Agilent TechnologiesA$48.75B24.5%34.3+54.18%
Mettler-Toledo InternationalMTD$34.07B27.8%37.2+66.04%
IDEXX LaboratoriesIDXX$55.2B32.5%46.8+30.53%
Labcorp HoldingsLH$30.24B11.2%30.5+47.06%

Same industry or related industries, similar size. Compare IQVIA Holdings with its competitors · Full profile